- Home
- PWR vs EW Comparison
PWR vs EW Comparison
Compare PWR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- EW
- Stock Information
- Founded
- PWR 1997
- EW 1958
- Country
- PWR United States
- EW United States
- Employees
- PWR N/A
- EW N/A
- Industry
- PWR Engineering & Construction
- EW Industrial Specialties
- Sector
- PWR Industrials
- EW Health Care
- Exchange
- PWR Nasdaq
- EW Nasdaq
- Market Cap
- PWR 41.3B
- EW 42.1B
- IPO Year
- PWR 1998
- EW 2000
- Fundamental
- Price
- PWR $254.15
- EW $70.91
- Analyst Decision
- PWR Strong Buy
- EW Buy
- Analyst Count
- PWR 19
- EW 21
- Target Price
- PWR $325.94
- EW $79.95
- AVG Volume (30 Days)
- PWR 1.7M
- EW 4.6M
- Earning Date
- PWR 05-01-2025
- EW 04-24-2025
- Dividend Yield
- PWR 0.16%
- EW N/A
- EPS Growth
- PWR 20.60
- EW 202.39
- EPS
- PWR 6.03
- EW 6.97
- Revenue
- PWR $23,672,795,000.00
- EW $5,439,500,000.00
- Revenue This Year
- PWR $14.68
- EW $10.16
- Revenue Next Year
- PWR $9.71
- EW $9.73
- P/E Ratio
- PWR $42.17
- EW $30.30
- Revenue Growth
- PWR 13.36
- EW 8.57
- 52 Week Low
- PWR $227.11
- EW $58.93
- 52 Week High
- PWR $365.88
- EW $95.73
- Technical
- Relative Strength Index (RSI)
- PWR 41.68
- EW 49.31
- Support Level
- PWR $250.68
- EW $70.32
- Resistance Level
- PWR $279.75
- EW $72.29
- Average True Range (ATR)
- PWR 9.44
- EW 1.50
- MACD
- PWR 1.64
- EW 0.19
- Stochastic Oscillator
- PWR 41.06
- EW 72.23
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric infrastructure and underground utility and infrastructure.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.